Ompenaclid (RGX-202) is an oral small-molecule inhibitor of the creatine transporter SLC6A8 used as a research compound and reference standard in preclinical studies. It inhibits creatine import, reduces intracellular phosphocreatine and ATP, and has demonstrated tumor apoptosis induction in model systems.
- Inhibits SLC6A8 creatine transporter in vitro and in vivo.
- Reduces intracellular phosphocreatine and ATP levels.
- Induces tumor cell apoptosis in preclinical studies.
- Available as high-purity solid or solution for research use.
- Characterized by confirmed molecular formula and molecular weight.